<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200915048732N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-12-03</date_registration>
      <primary_sponsor>Shiraz University of Medical Sciences</primary_sponsor>
      <public_title>The evaluation of the additive value of cognitive task on whole body vibration on balance and cognition in multiple sclerosis</public_title>
      <acronym></acronym>
      <scientific_title>The evaluation of the additive value of performing cognitive task while inducing whole body vibration on balance indices and cognition in multiple sclerosis patients</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-01-20</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>40</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/50974</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Participants will be assigned to each group by applying Random Allocation software, in a blocking method (size of 4). Group allocation will be defined in a block of four (2 participants in each group) and continue to put all 40 participants into two groups of Intervention and control, Blinding description: Data analyser and the physiotherapist who will measure the outcome measures, will be blinded to the patient’s allocation group.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Multiple sclerosis.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Patients are treated for 6 weeks, 3 sessions per week, 5 set per session by whole body vibration apparatus at the same time as performing Stroop cognitive task. In this task, congruent and incongruent colored words will be shown to the patients randomly in each trial. In the congruent condition the word and its color are the same and in the incongruent condition the word and its color will be different. For example, the word "blue" will be displayed in a different color; for example, with yellow color letters. Vibration rate in the first 2 weeks 5 set of 30 seconds with 1 minute break between sets, in the second 2 weeks 5 set of 45 seconds with 1 minute break between sets and in the third 2 weeks 5 set of 1 minute with 1 minute break is between sets. Intervention 2: Control group: This group is treated by only whole body vibration apparatus. Vibration rate is as the same as intervention group.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no more information.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mahsa Badpa</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Rehabilitation School of Shiraz University of Medical Sciences, Abiverdi 1 St., Chamran Blvd.</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>33669-71947</zip>
        <telephone>+98 71 3627 1551</telephone>
        <email>m_badpa@sums.ac.ir</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr. Mohsen Razeghi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Rehabilitation School of Shiraz University of Medical Sciences, Abiverdi 1 St., Chamran Blvd.</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>33669-71947</zip>
        <telephone>+98 71 3627 1551</telephone>
        <email>razeghm@sums.ac.ir</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age range of 20-50 years
A definite diagnosis of MS, Relapsing-remitting type, as diagnosed by a neurologist
Patients with mild to moderate disability (EDSS = 1-5.5) who are able to stand or ambulate independently. (ambulate at least 100 meters independently without aids or assistance)
Literacy
Fluent and understandable speech</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>50 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Pregnancy
A positive history of having fracture and implant in the knee and hip joints
History of epilepsy
Malignant tumors
Corticosteroid injection 28 days before the intervention
Severe osteoporosis
Discopathy, Acute protrusion, Spondylolisthesis
Severe diabetes
Severe wounds and scarring
Any musculoskeletal or neurological conditions except MS limiting balance
Uncorrected auditory or visual impairment
Disorders of the vestibular system at the diagnosis of a specialist
Severe mental disorders that lead to impossibility of cooperation of the participant.
Using drugs which affecting balance
Vertigo
History of attacks and relapses during the past 2 months
Having experience of vibration during the last 3 months
Receive physiotherapy interventions simultaneously or up to 1 month before the start of the research project</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>G35</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Multiple sclerosis</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Rehabilitation</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Patients are treated for 6 weeks, 3 sessions per week, 5 set per session by whole body vibration apparatus at the same time as performing Stroop cognitive task. In this task, congruent and incongruent colored words will be shown to the patients randomly in each trial. In the congruent condition the word and its color are the same and in the incongruent condition the word and its color will be different. For example, the word "blue" will be displayed in a different color; for example, with yellow color letters. Vibration rate in the first 2 weeks 5 set of 30 seconds with 1 minute break between sets, in the second 2 weeks 5 set of 45 seconds with 1 minute break between sets and in the third 2 weeks 5 set of 1 minute with 1 minute break is between sets.</i_keyword>
      <i_keyword>Control group: This group is treated by only whole body vibration apparatus. Vibration rate is as the same as intervention group.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Static balance. Timepoint: Before and after intervention. Method of measurement: Biodex balance system.</prim_outcome>
      <prim_outcome>Dynamic balance. Timepoint: Before and after intervention. Method of measurement: Biodex balance system.</prim_outcome>
      <prim_outcome>Functional balance. Timepoint: Before and after intervention. Method of measurement: Mini Balance Evaluation Systems Test (Mini- BESTest).</prim_outcome>
      <prim_outcome>Balance confidence. Timepoint: Before and after intervention. Method of measurement: Activities Specific Balance Confidence scale (ABC).</prim_outcome>
      <prim_outcome>Risk of falling. Timepoint: Before and after intervention. Method of measurement: Biodex balance system.</prim_outcome>
      <prim_outcome>Cognitive performance. Timepoint: Before and after intervention. Method of measurement: Montreal Cognitive Assessment Test (MOCA), Symbol Digit Modalities Test (SDMT).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Quality of life. Timepoint: Before and after intervention. Method of measurement: Multiple Sclerosis Quality of Life-54 Questionnaire (MSQoL-54).</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shiraz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-05-20</approval_date>
        <contact_name>Ethics committee of Shiraz University of Medical Sciences</contact_name>
        <contact_address>Rehabilitation School of Shiraz University of Medical Sciences, Abiverdi 1 St., Chamran Blvd. Shiraz Fars Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
